Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer

BACKGROUND: Nivolumab offers a superior survival benefit over docetaxel in patients with advanced, previously treated non-small-cell lung cancer (NSCLC). An association between programmed cell death ligand-1 (PD-L1) expression and the efficacy of nivolumab has been reported in many studies. However,...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Oncotarget
मुख्य लेखकों: Oya, Yuko, Yoshida, Tatsuya, Kuroda, Hiroaki, Mikubo, Masashi, Kondo, Chiaki, Shimizu, Junichi, Horio, Yoshitsugu, Sakao, Yukinori, Hida, Toyoaki, Yatabe, Yasushi
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Impact Journals LLC 2017
विषय:
Research Paper
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5732716/
https://ncbi.nlm.nih.gov/pubmed/29262550
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.21602
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन